The BioMelbourne Network and WEHI present – Advances in Cancer Therapeutics

New combinations of therapeutic agents for oncology are delivering positive results for patients and attracting strong interest from global pharmaceutical partners. What’s in the R&D pipeline for clinical oncology? Hear from Dr Malcolm McColl, CEO Viralytics (ASX:VLA) and Dr Warwick Tong, Cancer Therapeutics CRC on recent deals and collaborations with international partners to advance novel cancer therapeutics.

In one of the biggest preclinical deals in Australian biotech history, the Cancer Therapeutics CRC along with international partners announced their PRMT5 cancer drug program earlier this year. Dr Warwick Tong from Cancer Therapeutics CRC will be providing insights around the PRMT5 deal with Merck and lessons learnt whilst traversing the valley of death.

Dr Malcolm McColl, managing director and chief executive officer at Viralytics, will discuss their approaches using Cavatak oncolytic virus in combination with checkpoint inhibitors including collaboration with Merck (MSD) on clinical trials.

Date: Thursday 8th September, 2016

Time: 7.15am registration for 7.30am buffet breakfast followed by a 8am-9am presentation
Venue: The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville VIC 3052

Speakers:

Dr Warwick Tong, MB, ChB, MPP, GAICD, Chief Executive Officer, Cancer Therapeutics CRC (CTx)
Dr Malcolm McColl, Managing Director and Chief Executive Officer, Viralytics

Members – $65
Non-Members – $130
(Prices include GST)

To check if your organisation is a member click here

Supported by:

About our Speakers:

Dr Warwick Tong, MB, ChB, MPP, GAICD, Chief Executive Officer, Cancer Therapeutics CRC (CTx)

Dr Tong brings more than 19 years experience of senior leadership in medical, clinical, commercial and business development in the major pharmaceutical and biotechnology sectors.

From 2005 to 2011 he was SVP, Development, for Surface Logix Inc, Boston USA. Previously he held positions of increasing seniority at GlaxoSmithKline (GSK), including country, regional and global roles as Medical Director, Business Development Director and VP Commercial Strategy for Infectious Disease. Before his pharmaceutical industry career he worked in primary care medicine for 14 years, founding two medical clinics in New Zealand.

He graduated as Senior Scholar in Medicine from Auckland University, New Zealand and has a postgraduate qualification in Public Policy from Victoria University, Wellington New Zealand.

Dr Malcolm McColl, Managing Director and Chief Executive Officer, Viralytics

Dr McColl has more than 20 years’ management experience in the pharmaceutical and biotechnology industries, serving in senior level business development positions at both international and regional companies, with a focus on the oncology field.

Prior to joining Viralytics in 2013, he was Vice President Business Development at Starpharma, where he led partnering activities and programs. From 2007 to 2010, he served as Director of Business Development for global healthcare company, Hospira (formerly Mayne Pharma and acquired by Pfizer in 2015), where he was responsible for Europe, The Middle East and Africa. In this UK-based position, he led negotiations for licensing and acquisition transactions primarily in the oncology field. Previously, he was Hospira’s Director of Business Development for the Asia/Pacific region, completing multiple partnering transactions and contributing to strong revenue growth in the region.

Dr McColl also spent 13 years at CSL, a global specialty biotherapeutics company, culminating in his US-based role as Global Vice President, Business Development for the Animal Health Division. In this position, he played a lead role in the strategic development and globalisation of the Animal Health business, including entry into the US market. Dr McColl holds a first class honors degree in Veterinary Science from Melbourne University and an MBA from the Melbourne Business School.